Medicure Stock Price, News & Analysis

Medicure Inc. announced the results of its Annual General Meeting held on June 16, 2022, where new directors were elected, including James Kinley, and Ernst & Young LLP was re-appointed as auditor. CEO Albert Friesen expressed gratitude toward departing director Manon Harvey. Medicure focuses on pharmaceutical development for the U.S. cardiovascular market, marketing AGGRASTAT® and ZYPITAMAG®. The company operates Marley Drug, a North Carolina pharmacy that serves patients across the U.S., aiming to improve health outcomes and reduce costs.

Medicure reported Q1 2022 results with total net revenue of $5.7 million, up from $4.9 million in Q1 2021. The company saw strong sales from AGGRASTAT® ($2.8 million) and ZYPITAMAG® ($1.0 million), the latter growing significantly from $161,000 in the previous year. Adjusted EBITDA surged to $1.2 million from $31,000, while net income reached $482,000, compared to a loss of $1.0 million a year prior. Medicure appointed Haaris Uddin as CFO, effective June 1, 2022, enhancing its financial leadership.

Medicure reported a substantial increase in total net revenue for the year ended December 31, 2021, reaching $21.7 million, a rise from $11.6 million in 2020. This growth was driven by higher sales of AGGRASTAT® and ZYPITAMAG®, with the latter achieving $3.1 million in revenue compared to $453,000 previously. The company also noted a net loss of $727,000, an improvement from $6.8 million in 2020. Adjusted EBITDA turned positive at $2.1 million, compared to a negative $3.9 million the prior year, reflecting operational improvements and increased revenues.

Medicure Inc. (TSXV: MPH, OTC: MCUJF) is set to announce its 2021 Year End Results on April 28, 2022, during a conference call at 7:30 AM Central Time. The company focuses on developing and commercializing pharmaceuticals for the U.S. cardiovascular market, particularly AGGRASTAT® and ZYPITAMAG®. They also operate Marley Drug, a pharmacy in North Carolina. The conference call will be accessible via the Medicure investor relations page, and management will address questions related to financial results during the Q&A session.

Medicure Inc. has announced the resignation of Chief Financial Officer David Gurvey, effective March 25, 2022. The company expressed gratitude for Gurvey's contributions and initiated a search for a new CFO. Dr. Neil Owens, the current Chief Operating Officer, will serve as the interim CFO. Medicure focuses on developing innovative pharmaceuticals for the U.S. market, with notable products such as AGGRASTAT and ZYPITAMAG. The company is also expanding its e-commerce capabilities for direct patient ordering.

Medicure Inc. (OTC: MCUJF) announces that its subsidiary, Marley Drug, will be the sole mail-order pharmacy for RxSpark™. This partnership aims to enhance access to discounted medications for Americans, particularly in light of COVID-19's impact on healthcare. Marley Drug offers home delivery of over 100 chronic care medications, with options for 6- and 12-month supplies at competitive prices. The initiative seeks to improve patient adherence and reduce overall healthcare costs. The partnership aligns with Medicure's goal of expanding its pharmaceutical reach in the U.S. market.

Medicure Inc. has launched a national E-Commerce pharmacy platform, Marley Drug, aimed at providing affordable medications to over 100 million uninsured Americans. The platform offers FDA-approved medications for home delivery across all 50 states, enabling users to manage their prescription history easily. Customers can purchase medications in extended supply fills of up to 12 months, with prices starting at $37 for 6 months. During the launch, select medications will be available for just $2 per month with free shipping. Medicure aims to enhance healthcare affordability and shareholder value.

Medicure reported Q3 2021 net revenue of $4.9 million, up from $3.5 million in Q3 2020, driven by sales of AGGRASTAT® and contributions from Marley Drug™. AGGRASTAT® revenue declined to $2.9 million from $3.4 million year-over-year, while ZYPITAMAG® revenues improved to $388,000. The adjusted EBITDA rose to $282,000 from $4,000 in Q3 2020. Despite a net loss of $946,000, a reduction from $1.05 million, unrestricted cash increased to $3.3 million. The company expects future revenue growth from ZYPITAMAG® and Marley Drug™.

Medicure Inc. (OTC: MCUJF) announced plans to launch a national direct-to-consumer E-Commerce pharmacy platform via Marley Drug™ before the end of 2021. This platform aims to offer FDA-approved medications, including ZYPITAMAG, at discounted prices with free delivery across all 50 states. Targeting over 120 million uninsured and underinsured Americans, the initiative seeks to improve medication access and address 'pharmacy deserts.' CEO Albert D. Friesen highlighted this as a significant step for the company that could enhance shareholder value by strengthening existing business lines.